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There are only two adult liver transplant programmes in sub-Saharan 
Africa, and both are in South Africa (SA). The absence of these services 
for a billion people in this region contrasts starkly with widespread 
access in high-income countries. In SA, the first programme was 
established in 1988 at Groote Schuur Hospital in Cape Town and the 
second programme in 2004 at Wits Donald Gordon Medical Centre 
(WDGMC) in Johannesburg.[1] WDGMC is uniquely situated as a 
private academic teaching hospital in the Faculty of Health Sciences at 
the University of the Witwatersrand. The hospital focuses on teaching 
and training of specialists and sub-specialists and the provision of 
specialist care, including liver transplantation. Access to the liver 
transplant programme is based on need and all adults are prioritised 
for transplantation based on the severity of their illness. Referrals are 
widely received from state and private facilities.
Survival data on adult orthotopic liver transplants (OLTs) from 
international programmes have been published. Survival rates 
differ between middle-income and high-income countries because 
the volume of transplant procedures is usually much larger in 
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Background. Liver transplantation is the standard of care for the treatment of liver failure worldwide, yet millions of people living in sub-
Saharan Africa remain without access to these services. South Africa (SA) has two liver transplant centres, one in Cape Town and the other 
in Johannesburg, where Wits Donald Gordon Medical Centre (WDGMC) started an adult liver transplant programme in 2004.
Objectives. To describe the outcomes of the adult liver transplant programme at WDGMC.
Methods.  This was a retrospective review of all adult orthotopic liver transplants performed at WDGMC from 16 August 2004 to 30 
June 2016 with a minimum follow-up of 6 months. The primary outcome was recipient and graft survival and the effect of covariates on 
survival. Kaplan-Meier survival analysis included all adults who underwent their first transplant for end-stage liver disease (ESLD) (N=275). 
Proportional hazards regression analysis using hazard ratios (HRs) was conducted to determine which covariates were associated with a 
significantly increased risk of mortality.
Results. A total of 297 deceased-donor liver transplants were performed during the study period; 19/297 (6.4%) were for acute liver failure 
(ALF) and the remainder were for ESLD. The median age of recipients was 51 years (interquartile range 41 - 59), and two-thirds were male. 
The most common cause of ESLD was primary sclerosing cholangitis. The median follow-up was 3.2 years, and recipient survival was 
characterised in the following intervals: 90 days = 87.6% (95% confidence interval (CI) 83.1 - 91.0), 1 year = 81.7% (95% CI 76.6 - 85.8), and 
5 years = 71.0% (95% CI 64.5 - 76.5). Allograft survival was similar: 90 days = 85.8% (95% CI 81.1 - 89.4), 1 year = 81.0% (95% CI 75.8 - 
85.2), and 5 years = 69.1% (95% CI 62.6 - 74.7). The most significant covariates that impacted on mortality were postoperative biliary leaks 
(HR 2.0 (95% CI 1.05 - 3.80)), recipient age >60 years at time of transplant (HR 2.06 (95% CI 1.06 - 3.99)), theatre time >8  hours (HR 3.13 
(95% CI 1.79 - 5.48)), and hepatic artery thrombosis (HR 5.58 (95% CI 3.09 - 10.08)). The most common infectious cause of death was 
invasive fungal infection.
Conclusions. This study demonstrates that outcomes of the adult orthotopic liver transplant programme at WDGMC are comparable with 
international transplant centres. Management of biliary complications, early hepatic artery thrombosis and post-transplant infections needs 
to be improved. Access to liver transplantation services is still extremely limited, but can be improved by addressing the national shortage 
of deceased donors and establishing a national regulatory body for solid-organ transplantation in SA.
S Afr Med J 2018;108(11):929-936. DOI:10.7196/SAMJ.2018.v108i11.13286
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high-income countries. The Cape Town 
programme published a 10-year review 
(1988 - 1998) of 44 adult OLT procedures 
with 1- and 5-year patient survival rates of 
72% and 61%, respectively.[1] There are no 
data for adult liver transplants in SA after that 
time, despite major changes in the care and 
available treatment of transplant patients.
Objectives
To critically review the outcomes, constraints 
and challenges that persist for the adult liver 
transplant programme at WDGMC.
Methods
A retrospective record review was conducted 
of all adult (≥18 years) deceased-donor 
OLTs performed from the first transplant 
on 16 August 2004 to 30 June 2016, 
with a minimum follow-up of 6 months 
(31 December 2016). Approval for the study 
was obtained from the Medical Human 
Research Ethics Committee at the University 
of the Witwatersrand (ref. no. M140840). 
Data were extracted and cross-referenced 
using multiple sources: patient files, 
regulatory registers, organ procurement 
records, pathology laboratory and radiology 
services, surgical operation reports and ward 
admission records. Vascular and biliary 
complications were only included if they 
were confirmed radiologically and required 
an intervention (radiological and/or surgi-
cal). Postoperative biliary and vascular 
complications were independently reviewed 
by a radiologist. For all mortalities, cause of 
death was ascertained from clinical records, 
registers and postmortem reports, where 
available.
The following transplant recipient data 
were collected: age (on day of transplant 
procedure); gender; population group 
(black, mixed race, Asian/Indian and 
white); height; weight; body mass index 
(BMI, kg/m2); cause of liver failure; time 
on wait list prior to transplantation (days); 
model for end-stage liver disease (MELD) 
score[2] at time of transplant; ABO blood 
group; health status at time of transplant: 
inpatient/outpatient, diabetes mellitus, 
vascular disease, ascites; date of transplant; 
first or repeat transplant; allograft/s received 
(whole/split liver); operation time; cold 
ischaemic time; postoperative surgical 
morbidity: re-exploration by laparotomy, 
biliary and vascular complications, primary 
non-function of allograft; biopsy-proven 
acute rejection (within the first 90 days); and 
recipient and allograft survival.
The following deceased-donor data were 
collected: age (on day of donation); gender; 
population group (as above); height; weight; 
BMI; ABO blood group; referral centre; 
length of hospital stay prior to donation; 
operation time for organ harvest; and cause 
of death. Donor data were used to calculate 
the donor risk index (DRI).[3] All donors 
were heart-beating and brainstem dead; 
there was no donation after cardiac death.
Study data were collected and managed 
using Research Electronic Data Capture 
(REDCap), which is a secure, web-based 
application designed to support data 
capture for research studies hosted at the 
Faculty of Health Sciences, University of the 
Witwatersrand.[4]
Statistical analysis
The DRI was calculated according to the 
formula provided by Feng et al.[3] Percentage 
missing data have been included in all results 
in accordance with the Strobe guidelines 
for observational data.[5] The association 
between primary sclerosing cholangitis 
and comorbid diseases was assessed 
using Fisher’s exact test. Overall survival 
estimates were determined by the Kaplan-
Meier method and there was no adjustment 
of the survival analyses for any variables. 
To determine whether there was an 
improvement in recipient survival over time, 
based on the premise that the unit would 
have undergone an initial learning curve, the 
survival analysis was divided into two eras. 
To ensure approximately equal numbers of 
transplants in each group, era 1 was from 
16 August 2004 to 30 June 2012 and included 
151 cases. Era 2 comprised all transplants 
performed from 1 July 2012 to 30 June 
2016 and included 146 cases. The effect of 
covariates on unadjusted recipient survival 
for first transplants in patients with non-
acute liver failure (ALF) was determined by 
Cox proportional hazards regression and 
included recipient age and BMI at transplant, 
recipient gender, DRI, allograft type, reci-
pient length of hospital stay, operation 
time, cold ischaemic time, MELD score 
pre-transplant, health status pre-surgery 
(diabetes mellitus, ascites), centre experience 
(era 1 v. era 2), postoperative biliary and 
vascular complications, and cause of chronic 
liver disease (alcoholic and non-alcoholic 
steatohepatitis, autoimmune hepatitis, 
malignancy, primary sclerosing cholangitis, 
hepatitis B or C). The continuous variables 
were categorised for this analysis. Data 
were analysed using SAS version 9.4 (SAS 
Institute, USA). The 5% significance level 
was used.
Results
Between 16 August 2004 and 30 June 2016, 
there were 297 adult OLTs performed at 
WDGMC. Since inception of the programme, 
there has been a steady growth in the number 
of transplants performed per year (Fig. 1). 
While most recipient referrals were from 
the private sector, the relative proportions 
from the state sector almost doubled in 
era 2 (16/146, 11.0%) compared with era 1 
(9/151, 6.0%). The majority of the procedures 
performed were liver-only transplants (293/ 
297, 98.7%), and of these 16/293 (5.5%) were 
split grafts. There were 3 combined liver-
kidney (1.0%), 1 combined liver-heart (0.3%) 
and 12 repeat transplants (4.0%).
Characteristics of all recipients at the 
time of the transplant are summarised in 
Table 1. Overall, the median age of recipients 
was 51 years, almost two-thirds were 
male, and the median MELD score was 17 
(interquartile range (IQR) 13 - 22). Nine 
percent of recipients had a MELD score >30. 
The indications for the transplant were ALF 
in 6.4% of cases (19/297) and end-stage 
liver disease (ESLD) in the remainder. Of 
the 6 patients who presented with drug-
induced liver failure in the ALF group, 3 
were HIV-positive with efavirenz-induced 
hepatotoxicity.
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Fig. 1. Adult orthotopic liver transplants performed per annum at Wits Donald Gordon Medical Centre 
from 16 August 2004 to 30 June 2016.
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Table 1. Characteristics of adult OLT recipients at the time of transplant
Variable Overall (N=297)
Referral site, n (%)
State 25 (8.4)
Private 272 (91.6)
Age (years), median (IQR) 51 (41 - 59)
Gender, n (%)
Male 173 (58.2)
Female 124 (41.8)
Population group, n (%)
White 204 (68.7)
Black 53 (17.8)
Indian/Asian 28 (9.5)
Mixed 8 (2.7)
Missing 4 (1.3)
Blood group, n (%)
O 138 (46.5)
A 112 (37.7)
B 33 (11.1)
AB 12 (4.0)
Missing 2 (0.7)
BMI (kg/m2), median (IQR) (N=292, 98.3%) 26 (23 - 31) 
Disease severity, n (%)
Ascites, present/missing 193 (65.0)/5 (1.7)
Diabetes mellitus (type 2 only, no type 1), present/missing 56 (18.9)/4 (1.3)
Vascular disease (cerebral, cardiac, peripheral), present/missing 32 (10.8)/24 (8.1)
Hospitalisation, yes/missing 52 (17.5)/43 (14.5)
Dialysis, yes/missing 12(4.0)/4 (1.3)
MELD score, median (IQR) 17 (13 - 22)
MELD score, n (%)
<10 31 (10.4)
10 - 20 168 (56.6)
21 - 30 68 (22.9)
>30 27 (9.1)
Missing 3 (1.0)
Cause of ALF, n (%) (N=19, 6.4%)
Primary non-function of allograft 8 (2.7)
Drug-induced 6 (2.0)
Infection 4 (1.4)
Acute Wilson’s disease 1 (0.3)
Cause of ESLD, n (%) (N=278, 93.6%)*
Cholestatic (biliary) cirrhosis
Primary sclerosing cholangitis 74 (24.9)
Primary biliary cirrhosis 20 (6.7)
Vanishing bile duct syndrome 6 (2.0)
Missing 1 (0.3)
Non-cholestatic cirrhosis
Non-alcoholic steatohepatitis 58 (19.5)
Alcoholic steatohepatitis 53 (17.8)
Autoimmune hepatitis 34 (11.4)
Hepatitis C 15 (5.1)
Hepatitis B 12 (4.0)
Cryptogenic 12 (4.0)
Other† 6 (2.0)
Malignancy
Hepatocellular carcinoma 23 (7.7)
Hepatic epithelioid haemangioendothelioma 2 (0.7)
Continued ...
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In the group with ESLD, the median time 
on the wait list was 54 days (IQR 23 - 130). 
As expected, primary sclerosing cholangitis 
was the most common aetiology (74/297, 
24.9%), followed by almost equal numbers of 
alcoholic (53/297, 17.8%) and non-alcoholic 
steatohepatitis (58/297, 19.5%). Patients 
with primary sclerosing cholangitis had a 
significantly higher prevalence of ulcerative 
colitis (26.4%; p<0.0001) and Crohn’s 
disease (9.7%; p<0.0001) compared with 
those who did not have primary sclerosing 
cholangitis, for whom the prevalences of 
ulcerative colitis and Crohn’s disease were 
1.4% and 0.5%, respectively. Malignancies, 
most commonly hepatocellular carcinoma, 
comprised 10.8% (32/297), with a similar 
proportion of chronic hepatotropic viral 
infections (9.4%, 28/297), of which hepatitis 
C was most frequent.
The deceased-donor pool comprised 
mostly young white males who died from 
trauma. This was reflected in the relatively 
low median DRI of 1.61 (IQR 1.37 - 1.90) 
(Table 2).
Postoperative surgical complications are 
detailed in Table 3. Primary non-function 
of the allograft occurred in 8 cases (2.7%). 
Approximately 20% of patients required an 
exploratory laparotomy post-procedure. 
Overall, the most frequent complications 
were of biliary origin (62/297, 20.9%). The 
biliary leak rate was 9.1% (27/297) and most 
leaks occurred within the first 90 days after 
transplant. Conversely, the biliary stricture 
rate was 13.1% (39/297) and most occurred 
after 90 days. By far the most common 
vascular complication was hepatic artery 
thrombosis (HAT), with an incidence rate 
of 3.7% (11/297) in the first 30 days post-
transplant.
Median follow-up was 3.2 years. Using the 
Kaplan-Meier method, recipient survival for 
first transplants for end-stage liver disease 
(n=275) was estimated at the following 
intervals: 90 days = 87.6% (95% confidence 
interval (CI) 83.1 - 91.0), 1 year = 81.7% (95% 
CI 76.6 - 85.8), and 5 years = 71.0% (95% 
CI 64.5 - 76.5). Allograft survival was simi lar: 
90 days = 85.8% (95% CI 81.1 - 89.4), 1 year = 
81.0% (95% CI 75.8 - 85.2), and 5 years  = 
69.1% (95% CI 62.6 - 74.7) (Fig. 2). While 
there was improved recipient survival in era 2 
compared with era 1, this was not statistically 
significant (p=0.095) (Fig. 3).
Using proportional hazards regression 
analysis, the following covariates were 
associated with a significantly increased 
risk of mortality: recipient age >60 years 
at time of transplant (compared with age 
18 - 39 years) (hazard ratio (HR) 2.06 (95% 
CI 1.06 - 3.99)); theatre time >8 hours 
(compared with 6 - 8 hours) (HR 3.13 (95% 
CI 1.79 - 5.48)); postoperative biliary leaks 
(HR 2.0 (95% CI 1.05 - 3.80)); any vascular 
complication (HR 3.78 (95% CI 2.30 - 
6.22)); and HAT (HR 5.58 (95% CI 3.09 - 
10.08)). There was no significant association 
with any aetiology of chronic ESLD and 
postoperative mortality (appendices 1 and 
2, available from the corresponding author 
on request: june.fabian@mweb.co.za). There 
was a substantial mortality risk associated 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Unadjusted adult OLTx survival for allograft and re ipient at WDGMC (first transplant 
only, non-acute liver failure aetiology, n=275)                                                          
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Fig. 2. Unadjusted adult orthotopic liver transplant survival for allograft and recipient at Wits Donald 
Gordon Medical Centre (first transplant only, non-acute liver failure aetiology, N=275)
Table 1. (continued) Characteristics of adult OLT recipients at the time of transplant
Variable Overall (N=297)
Hepatic embryonal sarcoma 1 (0.3)
Metastatic liver disease (colorectal cancer) 1 (0.3)
Cholangiocarcinoma 3 (1.0)
Ductal carcinoma (other than cholangiocarcinoma) 1 (0.3)
Missing 1 (0.3)
Venous outflow obstruction
Budd-Chiari syndrome 16 (5.4)
Metabolic
Alpha-1-antitrypsin deficiency 5 (1.7)
Haemochromatosis 4 (1.3)
Wilson’s disease 2 (0.7)
Oxalosis 2 (0.7)
Erythropoeitic porphyria 1 (0.3)
PFIC (type 2 – biopsy proven) 1 (0.3)
OLT = orthotopic liver transplant; BMI = body mass index; IQR = interquartile range; MELD = model for end-stage liver disease; ALF = acute liver failure; ESLD = end-stage liver disease;  
PFIC = progressive familial intrahepatic cholestasis.
*Values add up to more than 100% owing to multiple comorbidities.
†Autosomal dominant polycyctic kidney disease n=3, sarcoidosis n=1, drug-induced n=1, infectious cause suspected but not identified n=1.
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with ‘redo’ or second transplants (HR 4.6 
(95% CI 2.3 - 9.3)).
Postmortem reports were available for 
almost half of the recipients who died in the 
first 90 days (20/47). Infectious aetiologies 
were the most common primary cause of 
death (9/20), and a significant contributing 
factor in 4 additional cases. Allograft failure 
(5/20), pulmonary thromboembolic disease 
(2/20), myocardial ischaemia (2/20) and 
cerebrovascular accident (1/20) comprised 
the remaining primary causes of death 
(1 case was undetermined). When infection 
was cited as the primary cause of death, the 
lungs (n=4) and gut (n=4) were the most 
common sources. Fungi were the organisms 
most commonly identified post mortem, 
namely Candida (n=2), aspergillosis (n=4), 
blastomycosis (n=1) and mucormycosis 
(n=1). It could not be established whether 
these organisms were identified antemortem.
Discussion
In the adult OLT programme at WDGMC, 
patient and graft survival are comparable to 
local and international transplant centres. 
The Cape Town programme published a 
10-year review (1988 - 1998) of 44 adult 
OLT procedures with 1- and 5-year patient 
survival rates of 72% and 61%, respectively. [1] 
The improved survival observed in our 
programme, 81.7% at 1 year and 70.0% at 
5 years, is a more contemporary experience 
and may reflect a combination of advances 
in immunosuppressive therapy such as the 
advent of tacrolimus, and improvements in 
surgical experience with a relatively higher 
transplant volume. More recently, other 
middle-income countries such as Thailand, 
India and Brazil have published similar 
outcomes.[6-8] Collectively, it is difficult to 
compare the outcomes of middle-income 
countries with high-income regions such as 
Europe and the USA, as the transplant milieu 
is different and volumes are substantially 
smaller. However, while early survival rates 
(90 days and 1 year) do appear to be lower 
in middle-income countries, survival rates 
after 1 year are equivalent to high-income 
regions.[9-11]
The most common indication for liver 
transplant in our study was primary 
sclerosing cholangitis, followed by non-
alcoholic and alcoholic steatohepatitis. This 
was similar to the findings published from 
Cape Town, where the three most common 
indications for liver transplant were post-
necrotic and alcoholic cirrhosis, and primary 
sclerosing cholangitis.[1] In both SA sites, 
primary sclerosing cholangitis was the cause 
of ESLD in 22 - 25% of liver transplant 
recipients, compared with 5% in Europe and 
9% in the USA.[10-12] Cholestatic causes of 
liver failure are also less frequent indications 
for liver transplant in Asia, where hepatitis  B 
infection is the predominant cause of 
ESLD. [12] Internationally, post-transplant 
survival for patients with ESLD due to 
primary sclerosing cholangitis is usually 
better than for other causes, but this was 
not demonstrated in our study (appendix 1, 
available from the corresponding author 
on request: june.fabian@mweb.co.za).[10-12] 
One explanation may be that our sample 
size was relatively small. As an infectious 
cause of ESLD, hepatitis C (5.1%) was more 
common than hepatitis B (4.0%), which is 
unexpected in SA but may be explained by 
the predominance of white OLT recipients 
in this cohort.
The emergent cases of ALF secondary 
to fixed-dose combination antiretroviral 
therapy (ART) for treatment of HIV 
infection deserve mention. The spectrum 
of histopathological changes in patients 
presenting with drug-induced liver injury 
secondary to ART shows considerable 
variation. Biopsies in some patients show 
features of chronic hepatitis, including 
portal inflammation with or without lobular 
inflammation, and variable fibrosis, while 
in others the pathological injury is much 
more severe. Many patients recover with 
interruption of treatment, but in severe cases 
this complication can be catastrophic as 
access to liver transplantation is limited. 
The implications of ALF caused by fixed-
dose combinations of ART are particularly 
relevant as SA has the largest HIV treatment 
programme in the world.
Biliary complications are an important 
cause of postoperative morbidity and 
mortality, and the international incidence 
varies from 5% to 25%.[13,14] In our 
programme, the incidence of all biliary 
complications was relatively high (20.9%) 
(Table 1). Reported incidence rates for 
biliary leaks and strictures range from 5% 
to 10% and 9% to 12%, respectively.[14] Our 
results were consistent with these findings 
for biliary leaks (9.1%) and strictures 
(13.1%) (Table 3).
HAT is a dreaded complication of liver 
transplantation, with most cases occurring 
in the early post-transplant period. There is 
no standard definition of early HAT (eHAT), 
ranging from within 2 weeks to 100 days 
after liver transplantation. In a systematic 
review that defined eHAT as occurring 
within the first 2 months of transplant, a 
worldwide decline in incidence rates over 
time has been demonstrated, dropping to 
2.9% in adults in high-volume centres. Our 
eHAT rate of 3.7% was higher than the 
rates observed in high-volume centres but 
comparable to rates observed in other low-
volume centres (5.8%).[15]
Based on a limited autopsy series of 
deaths that occurred in the first 90 days, 
sepsis was unequivocally the most common 
primary cause of death, and the most 
frequent organisms identified post mortem 
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Fig. 3. Adult liver transplant recipient and allograft survival at Wits Donald Gordon Medical Centre 
(first transplant only, non-acute liver failure, N=275). Recipient survival: era 1: 90 days = 85.2% (95% 
CI 78.2 - 90.0) and 1 year = 76.1% (95% CI 68.1 - 82.2); era 2: 90 days = 90.2% (95% CI 83.8 - 94.2) 
and 1 year = 87.9% (95% CI 81.0 - 92.4). (CI = confidence interval.)
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were fungi. This has been described previously and raises some 
pertinent considerations for clinical practice such as whether certain 
high-risk individuals should receive antifungal prophylaxis, for 
example those undergoing ‘redo’ transplants or with a pretransplant 
MELD score of ≥20.[16] There are also diagnostic challenges because 
fungal infections may be missed without a tissue sample, such as a 
lung or liver biopsy specimen.[17] We currrently have a high index 
of suspicion for fungal infection in our programme and use trends 
in beta-D glucan and galactomannan levels to initiate broad-
spectrum antifungal therapy. Where possible, an attempt is made to 
obtain biopsy material to confirm the diagnosis of invasive fungal 
infection.
Despite favourable outcomes, the adult OLT programme at 
WDGMC faces numerous challenges. For countries north of our 
borders, there is no access to liver transplantation and this is 
unlikely to change in the immediate future. Both the SA transplant 
programmes are located in large urban cities, making access difficult 
for those who live in semi-urban and rural areas. Further restrictions 
to access are imposed by a two-tiered healthcare system that favours 
the private sector and a national paucity of organ donors. Although 
the liver transplant centre in Cape Town is located in the state 
sector, the volume of transplants performed annually is relatively 
low. Without active, high-volume participation by state hospitals 
in solid-organ transplantation, access to these services will remain 
limited. The hybrid programme at WDGMC makes provision for 
access to liver transplantation based on need, regardless of ‘payer’ 
status. This reflects an evolution of policy, based on the recognition 
that expansion of transplant services in the state sector has been slow 
and liver transplantation is a low-demand but resource- and cost-
intensive healthcare service. The increasing number of state patients 
seen in era 2 reflects this change and is welcomed.
The number of transplants performed annually at WDGMC 
is not limited by capacity or resources, but rather by a dearth of 
donors. This highlights one of the greatest barriers to increasing 
solid-organ transplant volumes in SA and can only be addressed if 
a multifaceted approach is fully endorsed by national government 
for: (i) widespread public engagement and education about organ 
donation; (ii) the establishment of active organ procurement 
programmes in all hospitals; (iii) developing more transplant centres; 
and (iv) expanding the deceased and living organ donor pool.
Table 2. Characteristics of deceased donors and the DRI
Variable Overall (N=297)
Age (years), median (IQR) (N=291, 98.0%) 34 (21 - 45)
Population group, n (%)
White 240 (80.8)
Black 23 (7.75)
Mixed 23 (7.75)
Indian/Asian 8 (2.7)
Missing 3 (1.0)
Gender, n (%)
Male 179 (60.3)
Female 118 (39.7)
BMI (kg/m2), median (IQR) (N=273, 91.9%) 25.5 (4.5)
Blood group
O 170 (57.2)
A 100 (33.7)
B 24 (8.1)
AB 3 (1.0)
Cause of death
Trauma 158 (53.2)
CVA 109 (36.7)
Anoxia 9 (3.0)
Other 19 (6.4)
Missing 2 (0.7)
Allocation of deceased-donor organ
Regional 193 (65.0)
National 104 (35.0)
DRI, n (%)
≤1.00 1 (0.3)
1.01 - 1.20 23 (7.7)
1.21 - 1.40 51 (17.2)
1.41 - 1.60 48 (16.2)
1.61 - 1.80 49 (16.5)
1.81 - 2.00 38 (12.8)
>2.00 48 (16.2)
Missing 39 (13.1)
DRI, median (IQR) 1.61 (1.37 - 1.90)
DRI = donor risk index; IQR = interquartile range; BMI = body mass index; CVA = cerebrovascular accident.
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Transplantation programmes require substantial resources, and 
prioritisation of these services within the national health agenda 
can be problematic, particularly in middle-income countries. The 
growth of such services may only be ethically justifiable if the 
outcomes achieved are comparable to an accepted standard. Auditing 
local practice as part of the governance process in each transplant 
unit, a national liver transplant registry, and establishing a national 
regulatory body for solid-organ transplantation would be appropriate 
first steps.
Study limitations
This study has some limitations. It was retrospective and there were 
missing data, particularly regarding post-transplant infection and 
early v. late causes of death. Most recipient referrals were from the 
private sector, so this sample cannot be regarded as representative 
of the SA population. However, this research has highlighted areas 
for improvement in our clinical practice, such as reducing biliary 
and vascular complications and addressing antifungal prophylaxis in 
high-risk individuals. It also exposes persistent systemic inequities 
that compromise access to this form of care for most South Africans 
and demonstrates the complexities of providing liver transplantation 
services in a middle-income country, which is relatively well-
resourced compared with other sub-Saharan African countries.
Conclusions
In this study, the outcomes of the adult liver transplant programme 
at WDGMC in Johannesburg were comparable with international 
centres. Primary sclerosing cholangitis was the most common 
cause of chronic ESLD, which concurs with similar findings from 
Cape Town, but differs from international findings in the East and 
the West. Risk factors associated with increased mortality were 
recipient age >60 years at the time of transplant, operation time 
>8 hours, development of postoperative biliary leaks and vascular 
complications, particularly hepatic artery thrombosis. The biliary 
Table 3. Postoperative complications in adult OLT transplant recipients
Complication Overall (N=297)
Primary non-function of allograft, n (%)
Yes 8 (2.7)
No 289 (97.3)
Re-exploration (via laparotomy), n (%)
Yes 56 (18.8)
No 239 (80.5)
Missing 2 (0.7)
Vascular complication, n (%)
Yes 39 (13.1)
No 257 (86.6)
Missing 1 (0.3)
Type of vascular complication (N=39, 13.1%), n (%)*
Portal vein thrombosis 11 (28.2)
5 early (≤ 30 days), 6 late (>30 days)
Portal vein stenosis 2 (5.1)
0 early, 2 late
Inferior vena cava thrombosis 3 (7.7)
2 early, 1 late
Inferior vena cava stenosis 3 (7.7)
0 early, 3 late
Hepatic artery thrombosis 19 (48.7)
11 early, 8 late
Hepatic artery stenosis 3 (7.7)
1 early, 2 late
Hepatic artery pseudoaneurysm 2 (5.1)
1 early, 1 late
Hepatic artery rupture 1 (2.6)
Biliary complication, n (%)
Yes 62 (20.9)
No 235 (79.1)
Type of biliary complication (N=62, 20.9%), n (%)*
Biliary leak 27 (43.6)
25 early (≤90 days), 2 late (>90 days)
Biliary stricture 39 (62.9)
12 early, 27 late
Acute biopsy-proven rejection of allograft, n (%)
Yes 22 (7.4)
No 275 (92.6)
OLT = orthotopic liver transplant.
*Values add up to more than 100% because some recipients had more than one complication.
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complication and eHAT rates were higher than those seen in high-
volume centres and remain areas for improvement. Inequities in 
access to care and low donor rates remain significant challenges for 
liver transplantation in SA.
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